Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 4/20 | 0.67 |
| ▸ | JAK2 | O60674 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | GSK3B | P49841 | 1/20 | 0.49 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.48 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | FBP1 | P09467 | 1/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15145623 | 0.85 | PIN1 (0.70) | PIN1MEN1KMT2AMAPTGSK3B | |
| SCHEMBL28214992 | 0.84 | PIN1 (0.62) | PIN1JAK2MEN1KMT2AMAPT | |
| SCHEMBL19958511 | 0.84 | PIN1 (0.72) | PIN1MEN1KMT2AMAPTHPGD | |
| SCHEMBL28112936 | 0.83 | PIN1 (0.57) | PIN1JAK2MEN1KMT2AMAPT | |
| SCHEMBL21647422 | 0.82 | PIN1 (0.62) | PIN1JAK2MEN1KMT2AMAPT | |
| SCHEMBL8298036 | 0.82 | PIN1 (0.72) | PIN1GSK3BFBP1 | |
| SCHEMBL656001 | 0.82 | PIN1 (0.72) | PIN1MEN1KMT2AMAPTGSK3B | |
| SCHEMBL13303630 | 0.82 | PIN1 (0.72) | PIN1MEN1KMT2AMAPTGSK3B | |
| SCHEMBL30306428 | 0.81 | BRD4 (0.58) | MEN1KMT2AMAPTABCG2SYK | |
| SCHEMBL18739955 | 0.81 | BRD4 (0.58) | MEN1KMT2AMAPTABCG2SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023723-A1 | Purinone derivatives for treating neurodegenerative diseases | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2009-01-22 | — | — | US | disclosed |
| US-20090023723-A1 | Purinone derivatives for treating neurodegenerative diseases | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2009-01-22 | — | — | US | disclosed |
| US-20090023723-A1 | Purinone derivatives for treating neurodegenerative diseases | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2009-01-22 | — | — | US | disclosed |
| WO-2007035873-A1 | PURINONE DERIVATIVES FOR TREATING NEURODEGENERATIVE DISEASES | PHARMACOPEIA, INC. (US) | 2007-03-29 | — | — | WO | disclosed |
| WO-2007035873-A1 | PURINONE DERIVATIVES FOR TREATING NEURODEGENERATIVE DISEASES | PHARMACOPEIA, INC. (US) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023723-A1 | Purinone derivatives for treating neurodegenerative diseases | ADORA2A, P2RX6, P2RX5 | PIN1 4654/4885JAK2 2663/4885MEN1 4714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.